Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lina Rodriguez Rosario

Neurology Melbourne, FL Medical Doctor

NPI 1144450164 CMS profile 652319

1223 Gateway Dr Ste 2G, Melbourne, FL 32901

Open in the dashboard

General payments

$68,662

489 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lina Rodriguez Rosario of Melbourne, FL is reported in the CMS Open Payments database as having received $68,662 across 489 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,110 57
2024 General $6,927 23
2023 General $593 18
2022 General $15,995 46
2021 General $18,291 105
2020 General $6,389 64
2019 General $10,356 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lina Rodriguez Rosario
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Lina Rodriguez Rosario were reported at $10,110. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Lina Rodriguez Rosario Neurology median Middle half National median
2019 $10,356 $474 $118–$2,177 $163
2020 $6,389 $367 $82–$2,309 $114
2021 $18,291 $438 $104–$2,547 $132
2022 $15,995 $442 $103–$2,388 $149
2023 $593 $464 $119–$2,312 $160
2024 $6,927 $468 $119–$2,323 $164
2025 $10,110 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $23,350 52 payments
  2. AbbVie, Inc. $16,791 69 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $12,781 14 payments
  4. Biohaven Pharmaceuticals, Inc. $9,070 15 payments
  5. UCB, Inc. $770 45 payments
  6. Sunovion Pharmaceuticals Inc. $434 22 payments
  7. SK Life Science, Inc. $328 10 payments
  8. Avanir Pharmaceuticals, Inc. $303 13 payments
  9. Eisai Inc. $280 16 payments
  10. Amgen Inc. $264 14 payments
  11. Other $4,290 219 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,964 38 payments
  2. Food and Beverage $9,499 445 payments
  3. Consulting Fee $1,000 2 payments
  4. Travel and Lodging $117 3 payments
  5. Education $81 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT $21,851 29 payments
  2. AJOVY Central Nervous System $15,614 22 payments
  3. UBRELVY $12,599 45 payments
  4. Ajovy Central Nervous System $7,453 18 payments
  5. QULIPTA $4,423 35 payments
  6. Briviact $618 35 payments
  7. APTIOM $411 22 payments
  8. AIMOVIG $400 23 payments
  9. NUEDEXTA $303 13 payments
  10. FYCOMPA $260 10 payments
  11. Other $4,785 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

2,807

Median for Neurology: 833

Drug cost

$944,314

Median for Neurology: $202,670

Branded share of claims

27.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 17 $189,334
Lamictal Xr Lamotrigine Brand 14 $83,069
Xcopri Cenobamate Brand 11 $66,290
Nayzilam Midazolam Brand 24 $65,551
Briviact Brivaracetam Brand 35 $63,665
Qulipta Atogepant Brand 41 $58,760
Rexulti Brexpiprazole Brand 33 $47,612
Fycompa Perampanel Brand 17 $31,728
Aimovig Autoinjector Erenumab-Aooe Brand 27 $30,508
Clobazam Generic 71 $28,517

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$106,444

Medicare's payments for the services billed

Medicare patients

412

Average age 71

Services billed

3,005

242 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 35%
Depression 34%
Diabetes 32%
Chronic kidney disease 29%
Osteoporosis 22%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $6,628
$6,628 — —
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $191
$191 17 —
QULIPTA
  • AbbVie, Inc. $38
$38 41 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $25
$25 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $18
$18 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

489 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record